Pharma's Almanac

4517 Articles Available

1 189

Investment

Altis Biosystems Announces Completion of a $3.1 Million Seed Investment Led by VentureSouth

PR-M08-20-NI-18

Liquid Biopsy

FDA Approves First Liquid Biopsy Next-Generation Sequencing Companion Diagnostic Test

PR-M08-20-NI-17

Microbiome

Seres Therapeutics Shares Positive Top Line Results

PR-M08-20-NI-16

COVID-19 Treatment

Neutrolis Announces Development of First-In-Class Treatment Targeting Neutrophil Extracellular Traps (NETs) for Patients With Severe COVID-19

PR-M08-20-NI-15

COVID-19 Clinical Trials

RLF-100 Clinical Trial Shows Rapid Recovery from Respiratory Failure Due to Coronavirus

PR-M08-20-NI-14

Expansion

Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site

PR-M08-20-NI-13

COVID-19 Vaccine

AstraZeneca Signs COVID-19 Vaccine Deal with Chinese Company

PR-M08-20-NI-12

FDA Approval

FDA Approves GSK’s BLENREP for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

PR-M08-20-NI-11

COVID-19 Vaccine

Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine

PR-M08-20-NI-11

Leadership

Premier Research Adds to Diverse Team of Oncology Experts

PR-M08-20-NI-12

Appointment

SK pharmteco Announces General Manager to SK biotek Ireland

PR-M08-20-NI-10

M&A

Clinical Ink Announces Its Acquisition by GI Partners

PR-M08-20-NI-09

Agreement

PPD Signs New Service Agreement with Pfizer

PR-M08-20-NI-08

Financing

PMV Pharma Closes $70 Million in Series D Financing

PR-M08-20-NI-07

Collaboration

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo Combination in Melanoma

PR-M08-20-NI-06

COVID-19 Vaccine Funding

Sanofi and GSK Selected for Operation Warp Speed to Supply United States Government with 100 Million Doses of COVID-19 Vaccine

PR-M08-20-NI-05

Investment

AlloVir Announces Pricing of Upsized Initial Public Offering

PR-M08-20-NI-04

COVID-19 Vaccine

Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine

PR-M08-20-NI-03

COVID-19

Sterling Signs Deal to Produce Potential COVID-19 Drug Candidate for Moleculin

PR-M08-20-NI-02

Investment

DFC to Sign Letter of Interest for Investment in Kodak’s Expansion Into Pharmaceuticals

PR-M08-20-NI-01

Sustainability

Vetter Achieves Carbon Dioxide-Neutral Levels

PR-M07-20-NI-42

Collaboration

AstraZeneca and Daiichi Sankyo Enter Collaboration to Develop and Commercialize New Antibody Drug Conjugate

PR-M07-20-NI-41

COVID-19 Vaccine Funding

Moderna Announces Expansion of BARDA Agreement to Support Larger Phase 3 Program for COVID-19 Vaccine

PR-M07-20-NI-40

COVID-19 Vaccine

Moderna Begins Phase 3 COVE Study of mRNA Vaccine Against COVID-19

PR-M07-20-NI-39

1 189

»